Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This trial is testing a new kind of imaging called [89Zr]DFO-YS5 positron emission tomography (PET) to see if it is safe and can detect a type of cancer called multiple myeloma. They are using a special substance called [89Zr]DFO-YS5 that has a tiny bit of radioactive material in it. This substance is injected into a vein to help doctors see different parts of the body. The [89Zr]DFO-YS5 targets a protein called CD46, which is found in certain cancer cells of multiple myeloma. The goal of this trial is to see if [89Zr]DFO-YS5 PET scans can be better at finding multiple myeloma.
This trial is testing a new kind of imaging called [89Zr]DFO-YS5 positron emission tomography (PET) to see if it is safe and can detect a type of cancer called multiple myeloma. They are using a special substance called [89Zr]DFO-YS5 that has a tiny bit of radioactive material in it. This substance is injected into a vein to help doctors see different parts of the body. The [89Zr]DFO-YS5 targets a protein called CD46, which is found in certain cancer cells of multiple myeloma. The goal of this trial is to see if [89Zr]DFO-YS5 PET scans can be better at finding multiple myeloma.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. [89Zr]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and [89Zr]DFO-YS5 PET scans may improve detection of multiple myeloma.
This phase I trial tests the safety of [89Zr]DFO-YS5 positron emission tomography (PET) imaging and how well it works to detect CD46 positive cancer cells in patients with multiple myeloma. [89Zr]DFO-YS5 is an imaging agent called a radiopharmaceutical tracer. A radiopharmaceutical tracer uses a small amount of radioactive material that is injected into a vein to help image different areas of the body. [89Zr]DFO-YS5 targets a specialized protein called CD46, which is in certain multiple myeloma cancer cells, and [89Zr]DFO-YS5 PET scans may improve detection of multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: